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Pediatric Rheumatology took birth in India with the for-
mation of an interest group of the Indian Academy of
Pediatrics and the first conference in 2001 in Mumbai.
Now 11 conferences old, it has about 200 members and
12 centers offering part time or whole time care.
With a population of over 1000 million, it may be
extrapolated from Western data that India should have
at least 400000 children with rheumatologic disease -
JIA, JDM, SLE and vasculitides (excluding KD and HSP)
Disease patterns are similar to a Western clinic and a
little over a third of children attending a rheumatology
clinic in Mumbai are diagnosed to have non rheumato-
logic musculoskeletal disease, notably leukemia, genetic
disorders and chronic pain syndromes. The term ‘muscu-
loskeletal medicine clinic’ seems more apt. Acute diseases
such as septic arthritis/osteomyelitis are probably filtered
at the primary care level and hence the clinic functions
mainly as a chronic or day care facility. Fluorosis, muscu-
loskeletal MDR tuberculosis, brucellosis and HIV asso-
ciated arthropathy are unique issues. Most centers report
declining trends of Rheumatic fever but an alarming
increase of KD with consequent IViG requirement. Rare
diseases such as hereditary fever syndromes are seen,
some possibly representing the vestiges of early European
colonization.
Individual trends differ with SOJIA and ERA forming
the bulk of JIA rather than OJIA. Uveitis is not a major
concern. Outcomes of individual diseases seem different
to the West with most centers in India reporting a milder
phenotype of JDM.
Paradoxically 80% of the world’s pediatric rheumatolo-
gists care for 20% of the world’s children and vice versa.
Our undergraduate teaching ignores rheumatology while
our post graduate teaching focuses more on acute cross
sectional care rather than chronic longitudinal care.
Patents usually reach through complex pathways of
referral, often having consulted adult orthopaedic sur-
geons or alternative medicine systems prior to their
visit, highlighting the need for increasing awareness
about our specialty to lay public. They often have to travel
300-500 km for a consultation. Consequently, delay in
diagnosis of various diseases, irregular follow up and fre-
quent usage of steroid prior to referral are common.
While raising money for one time use of IViG is still feasi-
ble (selfpaid or charity), a country with a per capita
income of 1219 USD and much larger problems is unable
to adapt treatment guidelines suggested by the West when
it comes to the use of biologicals and consequently lesser
studied drugs and treatment algorithms are resorted to.
The crunch for interested and trained personnel (at least
200) has been addressed through a 3 level process -Preach
-sensitizing large gatherings of pediatricians, Reach and
Teach-intensive weeklong courses to committed smaller
groups and Each to Each -one on one teaching through
fellowships. The results are slow but visible.
India can contribute to the world of pediatric rheuma-
tology through its sheer numbers and its English speaking
medical community thus providing an excellent collabora-
tive research and teaching opportunity to centers with
knowhow but lacking in numbers. The developed world
can help us through facilitating student exchange, conces-
sional diagnostic tests and courses, telemedicine, bulletin
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